Parkside Financial Bank & Trust
BankPosition in DNLI — Denali Therapeutics Inc.
CIK 1455267
SAINT LOUIS, MO
Position in DNLI
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$3,628
+$508 QoQ
Shares Held
189
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Parkside Financial Bank & Trust holds $38,701,001 across 131 Biotechnology names. DNLI ranks #42 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
1,329,164 | $36,817,842 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
735 | $328,206 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
4,890 | $316,040 | |
| 4 | TECH |
BIO-TECHNE Corp
|
3,722 | $194,511 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
194 | $149,891 | |
| 6 | MRNA |
Moderna, Inc.
|
1,807 | $91,794 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,050 | $88,116 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
2,310 | $75,167 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,628 | 189 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $3,120 | 189 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,744 | 189 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $2,098 | 150 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||